January 2026 in “Food Science and Human Wellness” Krill oil may help reduce prostate enlargement and growth.
March 2026 in “Journal of Translational Autoimmunity” Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
These medications for BPH have known risks and may have new side effects.
May 2026 in “Journal of Human Immunity” Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
September 2003 in “Reactions Weekly” 23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
December 2023 in “Research Square (Research Square)” 12-Methoxy carnosic acid from rosemary might be a good natural treatment for hair loss.
September 2018 in “The Journal of Urology” 39 citations
,
January 1977 in “Dermatology” The treatment cleared psoriasis in some patients but caused side effects in most.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
7 citations
,
January 2018 in “International Journal of Trichology” Taking 5 mg/day finasteride can cause side effects in women with hair loss, but these are usually mild and fade over time, making the treatment beneficial in the long run.
1461 citations
,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
February 2025 in “Expert Opinion on Drug Safety” Topical minoxidil may cause more side effects than currently listed, needing updated safety information.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
January 2025 in “JAAD International” Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.
Naproxen can cause serious lung issues, but high-dose aspirin might be safer.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
50 citations
,
December 2005 in “European Journal of Immunology” RXRα is crucial for proper immune response and links diet to immune function.
8 citations
,
January 2013 in “Medicinal chemistry” The compound 4c showed strong potential as an anticancer agent.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.